Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Investigating Adipose Tissue Changes and Weight Regain After Incretin-Based Therapy Cessation

FY 2024-25

Summary
Incretin therapies, based on glucagon-like peptide 1 (GLP-1) and glucose dependent insulinotropic peptide (GIP) have been widely used in the treatment of type 2 diabetes (T2D) and obesity. GLP-1 receptor agonists (GLP-1Ras) and GLP-1R/GIP receptor (GIPR) co-agonist therapies effectively lower body weight, control blood glucose and lipid levels, contributing to its popularity. Due to medication shortages, many individuals are experiencing inaccessibility to treatment. Emerging studies have shown that cessation of GLP-1Ras and GLP-1R/GIPR co-agonists result in weight regain and a reversal of treatment-induced lowering of blood glucose and lipid levels. However, the effects of treatment cessation on adipose tissue (AT) composition and function are not well studied. Therefore, I aim to determine if cessation of GLP-1R/GIPR co- agonist therapies results in dysfunctional AT and altered composition in high fat diet fed male mice. I hypothesize treatment cessation will result in altered AT regulatory pathways and structure. I have shown that cessation of GLP-1Ra chronic injections results in body weight and fat mass regain compared to placebo. Mice also experience glucose and lipid intolerance and reduced insulin sensitivity compared to when receiving GLP-1Ra injections. I have also shown that white AT mass increases after treatment cessation and white adipocytes increase in size but decrease in number after cessation. This suggests that AT responds to treatment cessation, however the exact mechanism and pathways involved in weight regain remains unclear. This work will identify changes in AT regulatory processes to determine the effects of GLP-1R/GIP co-agonist cessation and inform a better understanding of mechanisms of weight regain.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530181
Name
Bisnauth Abigail R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating Adipose Tissue Changes and Weight Regain After Incretin-Based Therapy Cessation
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adipose Tissue; Diabetes; Gip; Glp-1 Receptor Agonists; Glp-1r/Gip Co-Agonists; Incretin Hormones; Liraglutide; Obesity; Weight Loss; Weight Regain
Abstract
Incretin therapies, based on glucagon-like peptide 1 (GLP-1) and glucose dependent insulinotropic peptide (GIP) have been widely used in the treatment of type 2 diabetes (T2D) and obesity. GLP-1 receptor agonists (GLP-1Ras) and GLP-1R/GIP receptor (GIPR) co-agonist therapies effectively lower body weight, control blood glucose and lipid levels, contributing to its popularity. Due to medication shortages, many individuals are experiencing inaccessibility to treatment. Emerging studies have shown that cessation of GLP-1Ras and GLP-1R/GIPR co-agonists result in weight regain and a reversal of treatment-induced lowering of blood glucose and lipid levels. However, the effects of treatment cessation on adipose tissue (AT) composition and function are not well studied. Therefore, I aim to determine if cessation of GLP-1R/GIPR co- agonist therapies results in dysfunctional AT and altered composition in high fat diet fed male mice. I hypothesize treatment cessation will result in altered AT regulatory pathways and structure. I have shown that cessation of GLP-1Ra chronic injections results in body weight and fat mass regain compared to placebo. Mice also experience glucose and lipid intolerance and reduced insulin sensitivity compared to when receiving GLP-1Ra injections. I have also shown that white AT mass increases after treatment cessation and white adipocytes increase in size but decrease in number after cessation. This suggests that AT responds to treatment cessation, however the exact mechanism and pathways involved in weight regain remains unclear. This work will identify changes in AT regulatory processes to determine the effects of GLP-1R/GIP co-agonist cessation and inform a better understanding of mechanisms of weight regain.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bisnauth, Abigail R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~